Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma.

Cold Spring Harbor molecular case studies - 1 Mar 2017

Hsiao Susan J, Karajannis Matthias A, Diolaiti Daniel, Mansukhani Mahesh M, Bender Julia Glade, Kung Andrew L, Garvin James H

Abstract excerpt

Pleomorphic xanthoastrocytoma (PXA) is a World Health Organization (WHO) Grade II glioma occurring primarily in children and young adults. Most PXAs harbor the known activating mutation BRAF V600E. We report a case of locally recurrent PXA with anaplastic features in a 10-yr-old female. The PXA was negative by immunohistochemical (IHC) staining for BRAF V600E mutation. Whole-exome and transcriptome sequencing of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exome Sequencing

Share to BRAF gene

Share to Glioma

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 28299358
DOI: 10.1101/mcs.a001396
PMCID: PMC5334470

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma.PMID 28299358Read ↗

BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.Semantic proximity Read ↗

BRAF/MEK Dual Inhibitors Therapy in Progressive and Anaplastic Pleomorphic Xanthoastrocytoma: Case Series and Literature Review.Semantic proximity Read ↗

Establishment and characterization of patient-derived xenograft from leptomeningeal spread of a rare pediatric anaplastic pleomorphic xanthoastrocytoma (PXA) bearing a CDC42SE2-BRAF fusionSemantic proximity Read ↗

A Rare Case of BRAF-mutated Metastatic Pleomorphic Xanthoastrocytoma Patient who Developed Radiodermatitis After Receiving Anti-BRAF Treatment.Semantic proximity Read ↗

Establishment and characterization of patient-derived xenograft of a rare pediatric anaplastic pleomorphic xanthoastrocytoma (PXA) bearing a CDC42SE2-BRAF fusion.Semantic proximity Read ↗

The evolution of pleomorphic xanthoastrocytoma: from genesis to molecular alterations and mimics.Semantic proximity Read ↗

Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.Semantic proximity Read ↗

Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma.Semantic proximity Read ↗

Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series.Semantic proximity Read ↗

Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.Semantic proximity Read ↗

Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.Semantic proximity Read ↗

Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.